Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Pichler, M; Lautsch, D; Adler, C; Bögl, K; Drexel, H; Eber, B; Fauer, C; Föchterle, J; Föger, B; Gansch, K; Grafinger, P; Lechleitner, M; Ludvik, B; Maurer, G; Mörz, R; Paulweber, B; Pfeiffer, KP; Prager, R; Stark, G; Toplak, H; Traindl, O; Weitgasser, R.
Are there differences in LDL-C target value attainment in Austrian federal states? Yes!
Wien Med Wochenschr. 2013; 163(23-24):528-535
Doi: 10.1007/s10354-013-0219-z
[OPEN ACCESS]
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Toplak Hermann
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Low density lipoprotein (LDL-C) levels determine the cardiovascular risk. Previous studies indicated an LDL-C target attainment of around 50%, but no Austrian wide analysis on results for the federal states was available. We therefore sought to detect potential differences. Open-label, non-interventional, longitudinal study, registered: www.clinicaltrials.gov NCT 01381679. In all, 746 statin treated patients not at LDL-C goal received intensified therapy for 12 months. The sample was split into nine subgroups, representing the federal states of Austria.We detected an east-west gradient for baseline LDL-C. Individual target values were achieved by 37.2% (range: 26.1-57.7%). After 12 months, LDL-C < 70 mg/l was achieved by 13.5% (5.9-38.5%). Univariate ANCOVA retrieved significant differences within the states (Upper Austria and Salzburg, p = 0.001 and p = 0.0015, respectively). Furthermore, the capacity of intensified lipid lowering therapy applied in practice was as high as -42% as compared to previous standard therapy (additional LDL-C reduction after switch from baseline therapy in Vorarlberg).
- Find related publications in this database (using NLM MeSH Indexing)
- Aged -
- Anticholesteremic Agents - therapeutic use
- Anticholesteremic Agents -
- Azetidines - therapeutic use
- Cholesterol, LDL - blood
- Cross-Sectional Studies -
- Drug Resistance -
- Female -
- Humans -
- Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use
- Hypercholesterolemia - blood
- Longitudinal Studies -
- Male -
- Middle Aged -
- Retreatment -
- Topography, Medical -